Nives Pustišek, EADV Spring Symposium 2021: Current Treatment Strategies in Atopic Dermatitis
We were delighted to speak with Dr Nives Pustišek (Children’s Hospital Zagreb, Croatia) about current treatment strategies in atopic dermatitis.
Her talk entitled ‘Treatment strategies in 2021: Atopic Dermatitis’ was presented at the EADV Spring Symposium, 6-7 May 2021.
- What are the keys to success with topical anti-inflammatory treatment? (0:15)
- What are the pros and cons of the current and emerging JAK inhibitors for atopic dermatitis? (1:55)
- Could you give us a brief overview of dupilumab and other upcoming biologic therapies, and their likely place in the therapeutic paradigm? (3:51)
- What is the recommended clinical approach to patients with refractory atopic dermatitis? (6:09)
Disclosures: Dr Nives Pustišek has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed as a highlight of EADV Spring Symposium 2021 (Virtual).
Share this Video
Related Videos In Atopic Dermatitis
Amy Paller, Dermatology Meeting News 2023: The efficacy of dupilumab in children with atopic dermatitis
Dupilumab is a monoclonal antibody approved for use in patients with atopic dermatitis that is not well controlled with topical treatments, or who are unable to use topical treatments. It was a pleasure to talk with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children’s Hospital of Chicago, Chicago, IL, USA) about the […]
Amy Paller, Dermatology Meeting News 2023: Current treatment paradigm for atopic dermatitis in children
Atopic dermatitis is a chronic skin disorder causing inflammation, redness and irritation of the skin, and usually begins in childhood. touchIMMUNOLOGY caught up with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children’s Hospital of Chicago, Chicago, IL, USA), to discuss the current treatment paradigm for atopic dermatitis in children, and factors that […]
Melinda Gooderham, Dermatology Meeting News 2023: Abrocitinib efficacy in atopic dermatitis by baseline disease severity – findings from an interim analysis of JADE EXTEND
JADE-EXTEND (NCT03422822) is a phase 3 long-term extension study investigating the efficacy and safety of abrocitinib in atopic dermatitis. In this touchIMMUNOLOGY interview, we caught up with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, Canada) around her interim analysis of JADE-EXTEND, looking at efficacy by baseline disease severity. The abstract ‘Influence of Baseline Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!